Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

Gene Therapy

Volumn 19, Issue 12, 2012, Pages 1133-1140

  Goyvaerts, C ^a   De Groeve, K ^a,b   Dingemans, J ^a,b   Van Lint, S ^a   Robays, L ^a   Heirman, C ^a   Reiser, J ^c   Zhang, X Y ^d   Thielemans, K ^a   De Baetselier, P ^a,b   Raes, G ^a,b   Breckpot, K ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

antigen presenting cell; lentiviral vector; Nanobody; targeting

Indexed keywords

ANTIBODY; CD11B ANTIGEN; CD123 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; GLYCOPROTEIN P 15095; LENTIVIRUS VECTOR; NANOBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LYMPH NODE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; VIRUS ENVELOPE;

ANIMALS; ANTIGEN-PRESENTING CELLS; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MACROPHAGES; MICE; SINGLE-DOMAIN ANTIBODIES; TRANSDUCTION, GENETIC;

EID: 84870815421     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.206     Document Type: Article

References (45)

1. Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy:targeting activation pathways through genetic modification. Endocr MetabImmune Disord Drug Targets 2009; 9: 328-343.
2. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol2009; 9: 259-270.
3. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells forcancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004;6: 1175-1188.
4. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for anti-tumorimmunotherapy. Curr Gene Ther 2008; 8: 438-448.
5. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C et al.Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.J Gene Med 2003; 5: 654-667.
6. Breckpot K, Emeagi P, Dullaers M, Michiels A, Heirman C, Thielemans K. Activationof immature monocyte-derived dendritic cells after transduction with high dosesof lentiviral vectors. Hum Gene Ther 2007; 18: 536-546.
7. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC et al.Modulation of human dendritic-cell function following transduction with viralvectors: implications for gene therapy. Blood 2005; 105: 3824-3832.
8. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S et al. HIV-1 lentiviralvector immunogenicity is mediated by TLR3 and TLR7. J Virol 2010; 84: 5627-5636.
9. Brown BD, Sitia G, Annoni A, Hauben E, Sergi Sergi L, Zingale A et al. In vivoadministration of lentiviral vectors triggers a type I interferon response thatrestricts hepatocyte gene transfer and promotes vector clearance. Blood 2007;109: 2797-2805.
10. Pichlmair A, Diebold SS, Gschmeissner S, Takeuchi Y, Ikeda Y, Collins MK et al.Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotypedlentiviral vector preparations carry DNA and stimulate antiviral responsesvia Toll-like receptor 9. J Virol 2007; 81: 539-547.
11. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG et al.Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptorviralRNA interactions. J Clin Invest 2005; 115: 3265-3275.
12. Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL et al.Induction of effective therapeutic antitumor immunity by direct in vivoadministration of lentiviral vectors. Gene Ther 2006; 13: 630-640.
13. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F et al. In vivoadministration of a lentiviral vaccine targets DCs and induces efficient CD8(+)T cell responses. J Clin Invest 2003; 111: 1673-1681.
14. He Y, Zhang J, Donahue C, Falo Jr LD. Skin-derived dendritic cells induce potentCD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.Immunity 2006; 24: 643-656.
15. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status andfuture potential. Arch Immunol Ther Exp (Warsz) 2010; 58: 107-119.
16. Frecha C, Levy C, Costa C, Negre D, Amirache F, Buckland R et al. Measles virusglycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescentlymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol2011; 85: 5975-5985.
17. Frecha C, Levy C, Cosset FL, Verhoeyen E. Advances in the field of lentivectorbasedtransduction of T and B lymphocytes for gene therapy. Mol Ther 2010; 18:1748-1757.
18. Frecha C, Costa C, Levy C, Negre D, Russell SJ, Maisner A et al. Efficient and stabletransduction of resting B lymphocytes and primary chronic lymphocyte leukemiacells using measles virus gp displaying lentiviral vectors. Blood 2009; 114: 3173-3180.
19. Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL et al. Stabletransduction of quiescent T cells without induction of cycle progression by anovel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008;112: 4843-4852.
20. Dreja H, Piechaczyk M. The effects of N-terminal insertion into VSV-G of an scFvpeptide. Virol J 2006; 3: 69.
21. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK. Single-chain antibodiesthat target lentiviral vectors to MHC class II on antigen-presenting cells. Hum GeneTher 2009; 20: 554-562.
22. Ageichik A, Buchholz CJ, Collins MK. Lentiviral vectors targeted to II MHC areeffective in immunization. Hum Gene Ther 2011; 22: 1249-1254.
23. Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L et al. Engineeredlentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008;26: 326-334.
24. Chandrashekran A, Gordon MY, Casimir C. Targeted retroviral transduction of ckit+hematopoietic cells using novel ligand display technology. Blood 2004; 104:2697-2703.
25. Yang L, Bailey L, Baltimore D, Wang P. Targeting lentiviral vectors to specific celltypes in vivo. Proc Natl Acad Sci USA 2006; 103: 11479-11484.
26. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, SongaEB et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-448.
27. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancertherapy. Expert Opin Biol Ther 2005; 5: 111-124.
28. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S,Conrath K. General strategy to humanize a camelid single-domain antibodyand identification of a universal humanized nanobody scaffold. J Biol Chem 2009;284: 3273-3284.
29. De Groeve K, Deschacht N, De Koninck C, Caveliers V, Lahoutte T, Devoogdt Net al. Nanobodies as tools for in vivo imaging of specific immune cell types. J NuclMed 2010; 51: 782-789.
30. Zhang XY, Kutner RH, Bialkowska A, Marino MP, Klimstra WB, Reiser J. Cell-specifictargeting of lentiviral vectors mediated by fusion proteins derived from Sindbisvirus, vesicular stomatitis virus, or avian sarcoma/leukosis virus. Retrovirology2010; 7: 3.
31. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J et al. Betalactamaseinhibitors derived from single-domain antibody fragments elicited inthe camelidae. Antimicrob Agents Chemother 2001; 45: 2807-2812.
32. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors throughpseudotyping. Curr Gene Ther 2005; 5: 387-398.
33. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature1998; 392: 245-252.
34. Katakai T, Hara T, Lee JH, Gonda H, Sugai M, Shimizu A. A novel reticular stromalstructure in lymph node cortex: an immuno-platform for interactions amongdendritic cells, T cells and B cells. Int Immunol 2004; 16: 1133-1142.
35. Nakamura K, Yamaji T, Crocker PR, Suzuki A, Hashimoto Y. Lymph nodemacrophages, but not spleen macrophages, express high levels of unmaskedsialoadhesin: implication for the adhesive properties of macrophages in vivo.Glycobiology 2002; 12: 209-216.
36. Goyvaerts C, Kochan G, Escors D, Breckpot K. Dendritic cells and lentiviral vectors:mapping the way to successful immunotherapy. Viral Gene Therapy ; pp 309-352.ISBN 978-953-307-539-6.
37. Funke S, Schneider IC, Glaser S, Muhlebach MD, Moritz T, Cattaneo R et al.Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteinsimproves titer and selectivity. Gene Ther 2009; 16: 700-705.
38. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B et al. Lentiviralvector retargeting to P-glycoprotein on metastatic melanoma through intravenousinjection. Nat Med 2005; 11: 346-352.
39. Coil DA, Miller AD. Phosphatidylserine is not the cell surface receptor for vesicularstomatitis virus. J Virol 2004; 78: 10920-10926.
40. Ziegler L, Yang L, Joo K, Yang H, Baltimore D, Wang P. Targeting lentiviral vectorsto antigen-specific immunoglobulins. Hum Gene Ther 2008; 19: 861-872.
41. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy:transforming infectious particles into therapeutics. Gene Ther 2007; 14: 847-862.
42. Fehse B, Roeder I. Insertional mutagenesis and clonal dominance: biological andstatistical considerations. Gene Therapy 2008; 15: 143-153.
43. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S et al. HIV-1 lentiviralvector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol2010; 84: 5627-5636.
44. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot Ket al. Dynamic bioluminescence imaging for quantitative tumour burdenassessment using IV or IP administration of D:-luciferin: effect on intensity, timekinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008;35: 999-1007.
45. Jeetendra E, Robison CS, Albritton LM, Whitt MA. The membrane- proximaldomain of vesicular stomatitis virus G protein functions as a membrane fusionpotentiator and can induce hemifusion. J Virol 2002; 76: 12300-12311.